The renin-angiotensin system may contribute to the development and progression of atherosclerosis both by increasing blood pressure and by direct effects on all phases of the atherogenic process. Genetic determinants of renin-angiotensin system activation, notably the DD genotype of angiotensin converting enzyme (ACE), are associated with an increased risk of cardiovascular events, as is increased plasma renin activity. In addition, angiotensin II has been shown to increase the uptake and oxidation of low density lipoprotein (LDL) by macrophages and endothelial cells. Angiotensin II also stimulates the production of interleukin 6 and activates the pro-inflammatory factor nuclear factor B , leading to expression of adhesion molecules and recruitment of monocytes and macrophages, and increases the production of pro-coagulatory factors. In
Introduction
Atherosclerosis is a complex process that may progress for several decades before becoming manifest as a cardiovascular event such as myocardial infarction. The process begins with endothelial dysfunction, which leads to monocyte activation and migration into the subintimal layer, lipid oxidation and uptake, foam cell accumulation, and the formation of fatty streaks, culminating in the development of an atherosclerotic plaque. 1, 2 Thrombus formation at the site of ruptured plaques, or intermittent thrombosis at intact plaques, leads ultimately to cardiovascular events. The risk of cardiovascular events resulting from atherosclerosis is influenced by a number of well established risk factors, including hypertension, 3 hypercholesterolaemia, 4 diabetes 5 and smoking. 6 In addition, there is increasing evidence that the renin-angiotensin system plays an important role in the development and progression of atherosclerosis, making this system a potentially animal experiments, treatment with ACE inhibitors or angiotensin AT 1 -receptor blockers has been shown to have anti-atherogenic effects. Studies with candesartan have shown that this agent produces a dose-dependent reduction in uptake of oxidised LDL by mouse macrophages in vitro, and reduces cholesterol accumulation and atherosclerosis development in the aorta of Watanabe rabbits. These effects were independent of changes in blood pressure. Such findings suggest that AT 1 -receptor blockers may be beneficial in reducing mortality and morbidity resulting from atherosclerotic disease, and are consistent with the findings from large outcome trials with ACE inhibitors in patients at risk of cardiovascular events. 
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Involvement of the renin-angiotensin system in atherogenesis
There is good evidence from epidemiological, laboratory and clinical studies that the renin-angiotensin system contributes to atherosclerosis not only by increasing blood pressure, but also through multiple direct effects on the arterial wall.
Effects on blood pressure
Angiotensin II, through its action on AT 1 -receptors, is a potent vasoconstrictor, 7 and can also increase blood pressure indirectly through activation of the sympathetic nervous system. 8 It is well established, from studies such as the Framingham Study 3 and the Multiple Risk Factors Intervention Trial (MRFIT), 9 that there is a continuous relationship between elevated blood pressure and the risk of cardiovascular events, and that lowering blood pressure reduces the risk of such events. 10 It appears, however, that a certain minimum level of blood pressure is necessary for atherosclerosis to develop. Atherosclerosis only occurs in high-pressure vascular beds. It does not, for example, develop in the pulmonary circulation except in the presence of pulmonary hypertension, and is not seen in veins, except in venous grafts in the arterial system. Furthermore, in patients with aortic coarctation, atherosclerosis is confined to the proximal segment, where pressure is high, and does not occur distal to the site of coarctation. The level of blood pressure required for atherosclerosis to develop has not been established. In the Hypertension Optimal Treatment (HOT) Study, the lowest incidence of major cardiovascular events (non-fatal stroke or myocardial infarction, and cardiovascular death) was seen at mean systolic and diastolic blood pressures of 138.5 mm Hg and 82.6 mm Hg, respectively, and the lowest risk of cardiovascular death at pressures of 138.8 mm Hg and 86.5 mm Hg, respectively.
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Evidence for direct effects of the renin-angiotensin system on atherogenesis Several lines of evidence suggest that the reninangiotensin system directly influences the risk of atherogenesis (Table 1) .
Genetic determinants of renin-angiotensin system activation:
Variations in the angiotensin converting enzyme (ACE) genotype have been shown to be associated with an increased risk of cardiovascular events. The most extensively studied of these variations is ACE I/D polymorphism. 12 This is characterised by the presence (I) or absence (D) of a 287 base pair sequence within intron 16 of the ACE gene, and the D allele is associated with increased ACE activity; in most populations, the DD genotype is associated with plasma ACE activity approximately 20 times higher than that observed in individuals with the DI genotype, and 40 times higher than in those with the II genotype. 12 Studies in countries with genetically homogeneous populations have shown that the DD genotype is associated with an approximately two to three-fold increase in the risk of cardiovascular events. For example, in a study in Turkey involving patients with previous myocardial infarction, the relative risk of 13 Similarly, in a study in Japan, the DD genotype occurred more commonly in patients with coronary artery disease than in healthy individuals (58% vs 42%, respectively), and the relative risk of myocardial infarction associated with the DD genotype was 2.81 (1.79-4.41, P Ͻ 0.001); 14, 15 in other Asian populations, the relative risk was 1.88 (1.43-2.48, P Ͻ 0.001). 12 In a large case-control study, involving 2267 male German caucasians, there was a strong association between the presence of the DD genotype and the risk of coronary artery disease, particularly in individuals without other risk factors. 16 Plasma renin activity: There is a well established relationship between elevated plasma renin activity and the risk of cardiovascular disease. In one study, for example, plasma renin activity was determined before starting antihypertensive treatment in 1717 patients with mild-to-moderate hypertension. 17 During the subsequent 8 years of antihypertensive therapy, a total of 27 myocardial infarctions occurred in these patients. After adjustment for age, gender and race, the incidence of myocardial infarction in patients with high plasma renin activity at baseline was 14.7/1000 person-years, compared with 5.6/1000 person-years among those with normal renin levels, and 2.8/1000 person-years in those with low plasma renin activity. Similarly, all-cause mortality was markedly higher among patients with high plasma renin activity than in those with normal or low renin activity (9.3, 5.3 and 3.9/1000 personyears, respectively). Multivariate analysis showed that elevated plasma renin activity was a powerful independent risk factor for myocardial infarction, but the risk was increased still further when other risk factors were present ( Figure 1 ).
Anti-ischaemic effects:
Large outcome studies with ACE inhibitors have consistently shown that these agents reduce cardiovascular mortality and morbidity in high-risk patients. [18] [19] [20] [21] [22] [23] In addition, however, these studies have shown that ACE inhibitor therapy reduces the incidence of recurrent myocardial infarction, by approximately 7-9% each year ( Figure 2 ). This finding suggests that ACE inhibitors have anti-ischaemic effects, probably related to stabilisation of atherosclerotic plaques.
Presence of ACE in atherosclerotic plaques:
Recent studies show that ACE is abundant at sites of atherosclerosis. In one study, for example, endarterectomy specimens were obtained from 24 patients with severe occlusive carotid artery disease, and ACE mRNA and protein were localised by in situ hybridisation and immunohistochemistry. 24 ACE was localised in the intima, and the degree of staining increased as lesions became more complex; the underlying media and smooth muscle were largely devoid of ACE. In 
Atherogenic effects of angiotensin II
Experimental data show that angiotensin II has multiple effects in the vessel wall that can contribute to the development and progression of atherosclerosis, including effects on lipid metabolism, inflammation, smooth muscle cell proliferation, and coagulation (Table 2) . 25 Effects on lipid metabolism: Angiotensin II has been shown to enhance the oxidation and uptake of low density lipoprotein (LDL) by macrophages and endothelial cells. 26, 27 Some of this activity may be mediated via the LOX-1 receptor, a recently discovered receptor for oxidised LDL that is present in vascular endothelium, and the expression of which is increased in atherosclerotic lesions. 28 Recent studies have shown that expression of this receptor is increased by angiotensin II and, conversely, expression of the AT 1 -receptor is up-regulated by oxidised LDL. 29 Effects on inflammation: Expression of interleukin (IL)-6 and other cytokines in vascular smooth muscle leads to recruitment of monocytes, which secrete enzymes such as collagenase and gelatinase, leading to plaque destabilisation. Inflammation thus plays an important role in destabilisation of the atherosclerotic plaque and the development of vascular events. Angiotensin II has been shown to stimulate IL-6 expression in vascular smooth muscle and human coronary atherosclerotic plaques. 30, 31 This effect is mediated via activation of nuclear factor (NF)-B , a pro-inflammatory factor that is required for expression of cytokines such as IL-6. 32, 33 Activation of NF-B also increases the production of various adhesion molecules that are involved in the recruitment of monocytes, such as vascular adhesion molecule (VCAM)-1 and intracellular adhesion molecule (ICAM)-1. This effect can be blocked by angiotensin AT 1 -receptor antagonists. In one study, for example, hypertensive transgenic rats were treated for 12 days with losartan, 10 mg/kg/24 h, hydralazine, 3 mg/kg/24 h, or saline. 34 Both active treatments significantly reduced endothelial cell injury in the thoracic aorta, but only losartan reduced the number of activated monocytes in the circulation and monocyte adhesion to the endothelium. These effects of AT 1 -receptor blockade were independent of changes in blood pressure.
Effects on smooth muscle migration and proliferation:
Angiotensin II induces the expression of autocrine growth factors such as basic fibroblastderived growth factor, platelet-derived growth factor and transforming growth factor-␤1, thereby stimulating vascular smooth muscle proliferation. 35, 36 In addition, angiotensin II contributes to vascular remodelling by modulating smooth muscle migration and inhibiting smooth muscle apoptosis (programmed cell death) in vascular tissue. 25 Effects on coagulation factors: Angiotensin II shifts the haemostatic balance towards an increased risk of thrombosis by increasing concentrations of plasminogen activator inhibitor (PAI-I) and reducing concentrations of tissue plasminogen activator (tPA). This effect can be blocked by ACE inhibitors or AT 1 -receptor antagonists. 37 In summary, angiotensin II has a number of atherogenic effects (Figure 3 ), which cause endothelial dysfunction, monocyte adhesion and release of inflammatory factors, foam cell formation, smooth muscle hypertrophy, and an increased risk of thrombosis. Angiotensin II thus affects all phases of the atherosclerotic process.
Anti-atherogenic effects of reninangiotensin system blockade
A number of studies have investigated the impact of AT 1 -receptor blockers or ACE inhibitors on the development and progression of atherosclerosis in animal models. A recent study, for example, has investigated the effects of AT 1 -receptor blockade in cynomolgus monkeys. 38 This species offers a number of advantages as a model of atherosclerosis. 
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Diet-induced atherosclerotic lesions are similar to those seen in the human coronary circulation, 39 and the development of these lesions follows a similar pattern to that seen in humans, progressing from foam cell accumulation and fatty streak formation. 40, 41 In the study by Strawn et al, 38 male cynomolgus monkeys were fed an atherogenic diet containing 0.067 mg cholesterol/kJ for 20 weeks. After 12 weeks, the animals were randomised according to their plasma cholesterol concentrations to receive losartan, 180 mg/day, or vehicle via osmotic minipumps for 6 weeks. Two weeks after the end of this treatment, the animals were killed and their aortas and other vessels removed for histological and immunohistochemical examination.
At the end of the study, there were no significant differences in blood pressure, total cholesterol concentrations, or plasma lipoprotein distribution between actively-treated animals and controls. However, monocyte CD11b expression in whole blood and isolated monocytes was significantly reduced by AT 1 -receptor blockade, indicating reduced monocyte activation and adhesion. AT 1 -receptor blockade also produced a significant increase in the lag time required for LDL oxidation in vitro, indicating decreased LDL uptake and oxidation. Furthermore, fatty streak formation in the aorta, the left anterior descending coronary artery, the left circumflex artery and the right coronary artery was reduced by approximately 50%, providing direct evidence that AT 1 -receptor blockade prevented the development of atherosclerosis in this model. This reduction in fatty streak formation was associated with a significant decrease in the cholesterol content of the carotid arteries.
In a second study, Watanabe heritable hyperlipidaemic rabbits were treated with the ACE inhibitor trandolapril, 0.25 mg/kg/48 h, between the ages of 3 and 12 months. 42 The development of atherosclerosis in the aorta was significantly reduced in trandolapril-treated animals, compared with controls: 35% of the total aortic intimal surface was affected by atherosclerosis, compared with 56% in control animals. Similar reductions were seen in the ascending aorta (82% vs 95%), the descending aorta (22% vs 54%) and the abdominal aorta (24% vs 39%). The cholesterol content in the descending aortic arch was significantly lower in trandolapril-treated animals than in controls, and atherosclerotic plaques from these animals appeared to contain fewer foam cells and more connective tissue than those from control animals. In this study, however, ACE inhibitor therapy produced a significant reduction in blood pressure, compared with the control group, and hence it is not possible to distinguish between the anti-atherogenic effects of blood pressure reduction and potential direct effects of ACE inhibition. This issue was addressed in a subsequent study, in which Watanabe rabbits were treated with the AT 1 -receptor blocker irbesartan at doses of 30 mg/kg/day and 75 mg/kg/day. 43 The lower dose of irbesartan had no significant effect on blood pressure, serum cholesterol or aortic atherosclerosis. By contrast, the higher dose produced a marked reduction in blood pressure, that was similar to that seen with the previous study with trandolapril. This was associated with significant reductions in aortic atherosclerosis and the cholesterol content of atherosclerotic plaques. In irbesartan-treated animals, 24% of the aortic intimal surface was affected by atherosclerosis, compared with 39% in control animals, and similar reductions were seen in the ascending, descending and abdominal aortic segments. The cholesterol content in the aorta was decreased from 27% to 17% in irbesartan-treated animals. These findings suggest that blood pressure reduction may contribute to the anti-atherogenic effects of AT 1 -receptor blockers. It should be noted, however, that irbesartan is not a fully insurmountable AT 1 -receptor antagonist, 44 and hence it is possible that the AT 1 -receptors were not permanently blocked in this study. As a result, some atherogenic actions of angiotensin II may still have been expressed in the presence of irbesartan.
Recent studies 45 have investigated the anti-atherogenic effects of candesartan, which acts as a fully insurmountable AT 1 -receptor antagonist. 44 In the first series of experiments, mouse macrophages from the J774A cell line were cultured and incubated for 3, 6 or 24 h with various concentrations of labelled oxidised LDL, with or without candesartan or angiotensin II. The cells were then washed repeatedly and the remaining radioactivity counted to determine uptake of oxidised LDL. Viability studies showed that the addition of angiotensin II or candesartan had no effect on cell growth. Angiotensin II produced a significant increase in the uptake of oxidised LDL, particularly at an oxidised LDL concentration of 50 g/ml (Figure 4 ). This effect was blocked by the addition of candesartan, 0.56 g/ml.
In subsequent experiments, incubation of macrophage cultures with a logarithmic series of candesartan concentrations resulted in a dose-related inhibition of oxidised LDL uptake ( Figure 5 ); candesartan concentrations above 0.56 g consistently reduced uptake of oxidised LDL by 70% or more. Such findings may have implications for clinical practice, suggesting that candesartan doses higher than those needed to control blood pressure may offer further beneficial effects in terms of prevention of atherosclerosis. In a second series of experiments, Watanabe rabbits were treated for 6 months with candesartan cilexetil, 2 mg/kg/day or atenolol, 10 mg/kg/day; a third group of animals served as controls. Blood pressure was measured at monthly intervals. At the end of the experiment, the animals were killed with pentobarbital and aortic segments removed for histological examination and determination of cholesterol and atherosclerotic plaque content. Neither Figure 7 Cholesterol content in the thoracic aorta of Watanabe rabbits treated for 6 months with candesartan cilexetil, 2 mg/kg/day, or atenolol, 10 mg/kg/day, and in control animals. Journal of Human Hypertension candesartan nor atenolol had any significant effect on blood pressure, compared with control animals. Candesartan treatment, however, was associated with a significant reduction in aortic atherosclerosis, compared with either atenolol-treated animals or controls ( Figure 6 ). In the thoracic aorta the mean area covered by atherosclerotic plaques was 18% in candesartan-treated animals, compared with 49% in atenolol-treated animals and 34% in the controls. Candesartan treatment was also associated with a significant reduction in the cholesterol content of the thoracic aorta, compared with both atenololtreated animals and controls (Figure 7 ). In these experiments, therefore, candesartan appeared to inhibit atherosclerosis by direct effects that were not related to changes in blood pressure.
Conclusions
Evidence from a number of sources indicates that the renin-angiotensin system contributes to the development of atherosclerosis by multiple mechanisms. Studies in experimental animals have shown that early treatment with AT 1 -receptor blockers can inhibit these mechanisms, thus preventing or reducing the development of atherosclerosis. Moreover, studies with candesartan and losartan indicate that these effects may be independent of changes in blood pressure. The finding that AT 1 -receptor blockers may prevent the development of atherosclerosis is consistent with the findings of numerous large clinical outcome trials, which have shown that ACE inhibitors reduce cardiovascular mortality and morbidity in high-risk patients.
